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Overexpression of the high-mobility group A (HMGA)1 and HMGA2 proteins is a feature
of all human pituitary adenoma (PAs) subtypes. However, amplification and/or rearrange-
ment of the HMGA2 have been described in human prolactinomas, but rarely in other
pituitary subtypes, and no genomic amplification of HMGA1 was detected in PAs. Here,
we summarize the functional role of HMGA proteins in pituitary tumorigenesis and the
epigenetic mechanisms contributing to HMGA overexpression in these tumors focusing
on recent studies indicating a critical role of non-coding RNAs in modulating HMGA
protein levels.
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Introduction
Pituitary tumors account for up to 25% of all diagnosed human brain tumors and the estimated
prevalence rate in the general population is about 17% (1). They can be classified in different
ways depending upon their size, radiographic appearance, endocrine function, morphology, and
cytogenesis. Based on the invasiveness, they are divided into (a) benign adenomas, representing the
majority of pituitary tumors that grow slowly, and rarely go toward the malignant phenotype; (b)
invasive adenomas, benign tumors that may spread to bones of the skull or the sinus cavity below
the pituitary gland; (c) pituitary carcinomas, which are malignant and spread into other areas of the
central nervous system (brain and spinal cord) or outside of the central nervous system. They are
extremely rare (2).
According to their size, pituitary adenomas (PAs) are classified into microadenomas (<10mm in
diameter), macroadenomas (>10mm), and giant adenomas (>40mm).
On the basis of their endocrine activity, PAs can be distinguished in hormone producing or
clinically non-functioning. About one-third of pituitary tumors are not associated with clinical
hypersecretory syndromes and they are called non-functioning pituitary adenomas (NFPAs).
Hormone-producing PAs release active hormones in excessive amounts into the bloodstream and
they are currently classified into five main immunohistochemistry (IHC) types: prolactinoma (PRL,
25–41%) somatotroph adenomas (GH, 10–15%), corticotroph adenomas (ACTH, about 10%),
thyrotroph adenomas (TSH, <1%), and gonadotroph adenomas (FSH-LH <1%), which can be
monohormonal or plurihormonal, with or without signs of hypersecretion (3).
Pituitary tumorigenesis is generally considered as a model of the multistep process of tumori-
genesis, in which molecular alterations represent the initializing event that transforms cells and
hormones and/or growth factors promote cell proliferation (1). Activation of oncogenes or loss of
tumor-suppressor genes, as well as alteration of cell cycle mediators and epigenetic modifications,
have been frequently reported to be involved in the pathogenesis of PAs (4).
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The great majority of PAs arise in a sporadic manner, and only
a minority of them is part of hereditary or familial syndromes.
The majority of adenomas arising in hereditary syndromes are
GH-secreting adenomas and they are associated toMEN-1 (linked
to somatic mutations of the tumor-suppressor gene MEN-1),
Carney’s complex (CNC) (linked to mutations of the tumor-
suppressor gene PRKAR1A), and McCune–Albright syndrome
(linked to activating mutations of the gsp oncogene). An activat-
ing mutation of the gsp oncogene is the most frequent genetic
alteration in sporadic tumors. It is a point mutation located in the
alpha subunit of the G-protein (GNAS), a stimulatory protein of
adenylylcyclase at the membrane level (5).
Pituitary tumor transforming gene (PTTG, also known as
securin) has been also implicated in pituitary tumorigenesis.
PTTG is largely expressed in functional human adenomas but not
in normal pituitary tissue (6) and its overexpression in transgenic
mice results in pituitary hyperplasia and adenoma formation (7).
GADD45γ has been the first identified tumor-suppressor gene
in pituitary tumorigenesis. GADD45γ is a negative regulator of
cell growth and it is not expressed in the majority of functional
and NFPAs (8). In addition, several animal models of cell cycle
regulators, such as pRB, CDKs, or CKIs, have demonstrated that
alterations of genes involved in cell cycle control are associated
with the development of PAs (9). Indeed,mice carrying genetically
modified alleles of the retinoblastoma (Rb) tumor-suppressor
gene, causing an increase in the E2F1 activity, showed high pre-
disposition to develop pituitary tumors (10), and this occurs also
in mice with impaired function of p27 or p18, both converging on
pRB pathway (11, 12).
Recently, two different research groups have identified novel
somatic mutations in the deubiquitinase gene USP8, all of them
harboring in the 14-3-3 protein binding motif and its nearby
region, in about one-third of corticotroph adenomas. Thesemuta-
tions enhanced the deubiquitinase catalytic activity of USP8, thus
protecting its numerous targets, such as EGFR, from the lysosomal
degradation and thereby leading to an enhanced activity of the
EGFR pathway (13, 14).
HMGA as Driver in the Development of
Human Pituitary Adenomas
The high-mobility group A (HMGA) family consists of four
proteins, HMGA1a, HMGA1b, HMGA1c, encoded by HMGA1
gene through alternative splicing, and HMGA2, encoded by the
homonymous gene. They are the most abundant non-histone
chromosomal proteins, also known as “architectural transcrip-
tional factors” since they do not possess a direct transcrip-
tional activity, but alter the chromatin structure through their
DNA-binding domains, called “AT hooks” (15), by which they
bind the minor groove of DNA in AT-rich sequences reg-
ulating, positively or negatively, the transcription of several
genes (16–18).
High-mobility group A proteins are expressed at high lev-
els during embryogenesis and at low levels in adult tissues,
whereas their expression is abundant in several human malig-
nant neoplasias (19). HMGA proteins have a causal role
in cell transformation. Indeed, their blocking by antisense
methodologies inhibits retrovirally induced malignant transfor-
mation of rat thyroid cells (20) while their enforced overexpres-
sion induces a transformed phenotype (21), and transgenic mice
overexpressing the HMGA proteins develop several benign or
malignant neoplasias (22–24).
The involvement of the HMGA genes, HMGA2 in particular,
in benign neoplasias has been widely reported. Rearrangements
of the HMGA2 gene were observed in human benign tumors of
mesenchymal origin, in which translocations involving the region
12q13–15 (where HMGA2 gene is located) have been frequently
detected (25, 26).
The first evidences of the role of HMGA2 in pituitary tumori-
genesis came from the observation that transgenic mice carry-
ing the HMGA2 gene under the transcriptional control of the
cytomegalovirus promoter developed PAs secreting prolactin and
growth hormone (23), more frequently in females than in males.
In addition, cytogenetic analysis of humanprolactinomas revealed
trisomy or tetrasomy of chromosome 12 associated with an ampli-
fication of the HMGA2 locus, which correlated with HMGA2
overexpression (27). Even though genomic amplification of the
HMGA2 gene was rarely found in PAs other than prolactino-
mas (28), the overexpression of HMGA1 and HMGA2 has been
reported in a significant number of PAs (29, 30). Moreover, the
level of HMGA2 protein has been found positively correlated
with tumor invasion and was significantly higher in grade IV
than in grades I, II, and III adenomas. High levels of HMGA2
expression were more frequently detected in macroadenomas
than in microadenomas and also significantly correlated with the
proliferation marker Ki-67 (31).
The mechanism by which HMGA overexpression induces the
development of PAs is the enhancement of the E2F1 activity (32).
This mechanism is quite unique; although HMGAs bind to the
pRB A/B pocket domain, they do not compete with the E2F1
protein in pRB binding, but displace HDAC1 from pRB/E2F1
complex, resulting in enhanced acetylation of both E2F1 and
DNA-associated histones, thereby promoting E2F1 activation.
The rescue of the adenomatous phenotype when transgenic mice
overexpressing theHMGA2 gene weremated with E2F1 knockout
mice confirmed the role of the enhanced E2F transcriptional
activity in the onset of PAs in HMGA transgenic mice (32).
Subsequent studies have demonstrated thatHMGA1 andHMGA2
can also affect cell cycle by regulating CCNB2, coding for cyclin
B2 (30). Indeed, HMGAs are able to directly regulate this gene
at transcriptional level, and, consistently, cyclin B2 overexpres-
sion was found in human PAs with a significant correlation
with HMGA expression. In addition, other mechanisms could
be responsible for the oncogenic role of HMGA in pituitary.
Among these, the increased expression of IL2 and its receptor
in pituitary cells by HMGA (22), and/or induction of the AP-1
activity by enhancing the expression of the AP-1 members FRA-
1 and JunB (33) cannot be excluded. Moreover, the pituitary-
specific transcription factor Pit-1 (POU domain, class 1, tran-
scription factor 1) was found overexpressed in PAs from Hmga1b
and Hmga2 transgenic mice. It has been also demonstrated that
Pit-1 is positively regulated by HMGA protein and its overex-
pression positively correlates with that of HMGA also in human
PAs (34).
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Epigenetic Control of HMGA Protein Levels
by Non-Coding RNAs
Overexpression of HMGA1 and HMGA2 proteins is a feature of
human PAs, and according to a crucial role of their overexpression
in pituitary tumorigenesis, transgenic mice overexpressing either
hmga1 or hmga2 develop PAs (24). However, while HMGA2
gene rearrangement and/or amplification was found in a certain
number of PAs (27, 28), no genomic alterations of the HMGA1
locus have been detected in PAs, even though overexpression of
both HMGA proteins has been described (30, 35, 36). Therefore,
other mechanisms accounting for HMGA overexpression in these
tumors might be envisaged. Recent studies indicated that both
the HMGA genes can be modulated by a novel class of epigenetic
regulators, known as non-coding RNAs (ncRNAs).
In the last 15 years, thanks to the advent of bioinformatic
approaches examining the human transcriptome, it came up that
about 70% of the genome is transcribed but only 2% of the human
genome is translated into proteins (37). The remaining large pro-
portion of DNA, initially referred to as “junk DNA,” was found to
be transcribed as ncRNAs.
Non-coding RNAs comprise multiple classes of RNA that
are not transcribed into proteins but have been shown to reg-
ulate transcription, stability, or translation of protein-coding
genes (38). They include microRNAs (miRNAs or miRs), tRNAs,
rRNAs, small nuclear RNAs (snRNAs), and heterogeneous group
of long non-coding RNAs (lncRNAs).
miRNAs Targeting HMGA Proteins
microRNAs are sncRNA molecules of about 22 nt, which induce
gene silencing by suppressing protein synthesis or by mRNA
degradation. To date, over 1,000 miRNAs have been identified
in humans, which regulate about 60% of mammalian genes (39).
Interestingly, each miRNA is able to target multiple mRNA
and, in turn, each mRNA can be regulated by several miRNAs
cooperatively.
microRNA-mediated repression of target gene occurs by per-
fect or imperfect complementarity with sequence motifs predom-
inantly found within the 30 untranslated regions (UTRs) of the
target mRNAs (40). Altered expression of miRNAs has been asso-
ciated with various human diseases, including cancer, in which
they can act as “onco-miR” or “tumor-suppressor-miR” (41).
Recent studies indicate a critical role of miRNAs in regula-
tion of HMGA expression. Indeed, reduced expression of let-7 is
reported in about 42% of PAs and has been inversely correlated
with HMGA2 expression and high-grade tumors (42). Subse-
quently, it has been demonstrated that miR-15, miR-16, miR-26,
miR-196a-2, and let-7a, which target both the HMGA genes, are
drastically downregulated in a panel of 41 human PAs of different
histotypes, and their expression is inversely correlated with the
HMGA expression.Moreover, enforced expression of theHMGA-
targeting miRNAs reduces cell growth of GH3, a rat GH/PRL
pituitary cell line, supporting their tumor-suppressor role (43).
Accordingly, the analysis of a miRNA expression profile of GH
adenomas versus normal pituitary has unveiled a set of miR-
NAs constantly deregulated in somatotroph tumors, comprising
miR-326, miR-432, and miR-570, targeting HMGA2, miR-34b,
and miR-548c-3p both having HMGA1 and HMGA2 as targets,
and miR-326 and miR-603 targeting E2F1. Their downregulation
was also found in PRL and gonadotroph adenomas, suggesting
that it represents a general event in pituitary tumorigenesis. Subse-
quent functional studies have confirmed the role of the downregu-
lation of these miRNAs in tumor growth and cell cycle regulation.
Indeed, a significant reduction of cell number and, accordingly, an
increase in the G1 phase population and a decrease in the S phase
were observed after transfection with the HMGA-targeting miR-
NAs. Finally, an inverse correlation was found between miRNA
expression and HMGA1 and HMGA2 protein levels in GH-
secreting adenomas, suggesting a possible role of these miRNAs
in the HMGA/E2F1 pathway, and thereby in the development
of PAs (44). Recently, it has been reported that also miR-23b,
which was found downregulated in GH, gonadotroph, and null
cell PAs, targets HMGA2, and that its overexpression inhibits cell
proliferation arresting cells in the G1 phase of cell cycle (45).
LncRNAs Regulating HMGA Proteins
Long non-coding RNAs are a class of transcribed RNAmolecules
ranging in length from 200 nt to ~100kb and lacking protein-
coding capability. Unlike mRNAs, which exhibit strong conser-
vation across diverse species, lncRNAs are generally poorly con-
served, they are preferentially expressed in tissue-specific manner
and they can regulate the transcription, stability, or translation of
protein-coding genes by differentways that have not been not fully
clarified yet (46).
Among the lncRNAs, pseudogenes are a class of RNAmolecules
that have lost their coding potential because of premature or
delayed stop codons, deletions/insertions, and frameshift muta-
tions that abrogate translation into functional proteins (47, 48).
They are classified in processed, if they were generated by
retro-transposition of the corresponding protein-coding mRNA,
or unprocessed, if they arise by gene duplication and then acquire
mutations making them non-functional. Since processed pseudo-
genes share 50 and 30 UTR sequences with their ancestral genes,
they can exert regulatory control of parental gene expression by
competing for the same miRNAs (49).
Recently, two HMGA1 non-coding processed pseudogenes,
HMGA1P6 and HMGA1P7, have been identified and charac-
terized. Both HMGA1P6 and HMGA1P7 have conserved seed
matches for miRNAs targeting HMGA1 and HMGA2 genes and
they work as competitive endogenous RNA (ceRNA), thereby
protecting HMGAs from the inhibition of protein expression
by miRNAs. Consistently, HMGA1 pseudogenes (Ps) also show
oncogenic activity by inhibiting apoptosis and increasing cell pro-
liferation and migration (50, 51). Moreover, a direct correlation
between HMGA1 and HMGA1Ps expression in a set of human
pituitary tumors, including somatotroph adenomas and NFPA or
gonadotroph FSH-LH tumors has been found. Functional stud-
ies have also demonstrated that both pseudogenes affect pitu-
itary cell proliferation and migration. Indeed, overexpression of
HMGA1P6 orHMGA1P7 reduced the growth rate of the pituitary
cell line AtT20 and, consistently with the role of HMGA1 in
promoting cell migration, their enforced expression increases the
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migration of the same cells, thus indicating that HMGA1 pseudo-
gene overexpression contributes to pituitary tumor development,
thereby disclosing an additional mechanism responsible for the
increased expression of HMGA1 in PAs (52).
A recent analysis of lncRNA expression in gonadotroph ade-
nomas has unveiled a list of differentially regulated lncRNAs.
Interestingly, among the most upregulated lncRNAs (fold-change
53,18 compared with normal pituitary) we found the RPSAP52
(ribosomal protein SA pseudogene 52) gene, which is the natu-
ral antisense of the HMGA2 gene. It belongs to the category of
the antisense lncRNAs, which are transcribed from the antisense
strand and partially overlap with the coding strand, and thereby
regulate expression of corresponding coding genes at transcrip-
tional or post-transcriptional level through various mechanisms
(53). Recent results demonstrate that the enforced expression of
RPSAP52 is able to increase the HMGA2 protein level, induces
cancer cell proliferation, and promotes cell cycle progression.
Conversely, downregulation of HMGA2 protein and decreased
proliferation rate of cancer cells were observed when RPSAP52
expression was inhibited by antisense oligonucleotides. Then,
RPSAP52 is able to positively regulate the associated HMGA2
gene, promoting its oncogenic activity, by mechanisms that are
currently under investigation.
Conclusion and Perspective
Taken together, the data overviewed here highlight the critical
role of HMGA1 and HMGA2 overexpression in the onset of PAs.
Moreover, the most recent studies evidence that aberrant HMGA
protein levels in PAs are also sustained by epigenetic mechanisms.
Indeed, it has been demonstrated that a set of miRNAs, constantly
and drastically downregulated in PAs, are able to target both the
HMGA genes. Interestingly, some of these miRNAs target also
E2F1 whose activation, at least in animal models, is a critical step
for PA development in transgenicmice overexpressing theHMGA
genes.
Very recently, it has been shown that twoHMGA1 pseudogenes
are overexpressed in PAs. Their overexpression protects both the
HMGA mRNAs from the miRNA-mediated downregulation of
HMGA genes. Functional studies support the role of miRNA
downregulation andHMGA1 pseudogene overexpression in pitu-
itary tumorigenesis. In fact, miRNA-restoration reduces the pro-
liferation rate of pituitary cell lines, with an increased G1 phase
FIGURE 1 |Mechanisms responsible for HMGA overexpression in
pituitary cell transformation. Schematic representation of genetic and
epigenetic mechanisms leading to overexpression of HMGA proteins in PAs.
of cell cycle, accordingly with a reduction of the HMGA expres-
sion. Conversely, HMGA1 pseudogene overexpression, acting as
ceRNA and protecting HMGAs from the inhibition of miRNAs,
promotes the HMGA oncogenic activity. Finally, preliminary
studies showed a drastic upregulation in PAs of the RPSAP52,
the lncRNA antisense of HMGA2, which also leads to increased
HMGA2 protein levels (Figure 1).
Then, all these data support an innovative therapy of the inva-
sive PAs, based on the impairment of theHMGAprotein function,
that could not only be achieved directly, by the use of specific short
interfering RNAs and/or drugs able to impair their activity, such as
trabectedin (54), but also indirectly, restoring the expression of the
HMGA-targeting miRNAs. Since miRNAs are able to target more
than one gene that often code for proteins that are involved in the
same or correlated pathways this last approachmight represent an
additional advantage for the antineoplastic therapy.
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